Drug Profile
Research programme: biosimilars - Merck & Co.
Alternative Names: Epoetin alfa biosimilar - Merck & Co.; INS-21; INS-22; Interferon beta-1b biosimilar - Merck & Co.Latest Information Update: 29 Aug 2013
Price :
$50
*
At a glance
- Originator Insmed
- Developer Merck & Co
- Class Antianaemics; Antineoplastics; Antivirals; Interferons; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Immunomodulators; Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia; Multiple sclerosis
Most Recent Events
- 29 Aug 2013 No development reported - Preclinical for Anaemia in USA (SC)
- 29 Aug 2013 No development reported - Preclinical for Multiple sclerosis in USA (SC)
- 01 Jan 2006 Preclinical trials in Anaemia in USA (SC)